# Social Impacts of Multi-City HIV Research Participation Among Sexual and Gender Expansive Individuals in Kazakhstan

- 3 Vitaliy Vinogradov, BA,<sup>a</sup> Yong Gun Lee, PhD, LMSW,<sup>a,b,c</sup> Gulnara Zhakupova, MSW,<sup>a</sup> Gaukhar 4 Mergenova, PhD, MD, MS,<sup>a</sup> Alissa Davis, PhD, MPH,<sup>a,c</sup> Emily Allen Paine, PhD,<sup>d</sup>, Kelsey G. Reeder, 5 LCSW, <sup>c</sup> Caitlin I. Laughney, PhD, MSW, <sup>d</sup> Jimin Sung, MA, <sup>c</sup> Sholpan Primbetova, MS, MPharm, <sup>a</sup> Assel 6 Terlikbayeva, MD, MS,<sup>a</sup> Jeremy Sugarman, MD, MPH, MA,<sup>e</sup> Elwin Wu, PhD, LMSW,<sup>a,c</sup> 7 8 <sup>a</sup> Columbia University Global Health Research Center of Central Asia, Almaty, Kazakhstan 9 <sup>b</sup> Department of Social Work and Social Administration, The University of Hong Kong, Hong Kong 10 <sup>c</sup> Social Intervention Group, Columbia University School of Social Work, New York, New York, USA 11 <sup>d</sup> Columbia University and New York State Psychiatric Institute, New York, New York, USA 12 <sup>e</sup> Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland, USA 13 14 **Corresponding author** 15 Yong Gun Lee, PhD, LMSW 16 Room 506, The Jockey Club Tower, The Centennial Campus, The University of Hong Kong, Pokfulam, 17 Hong Kong 18 +852 3917 1185 19 yglee@hku.hk 20 21
- 22 **Presentation history**
- Parts of the data were presented at the IAS 2023, 12th IAS Conference on HIV Science, Brisbane,
- Australia, July 23-26, 2023 (<u>https://programme.ias2023.org/Abstract/Abstract/?abstractid=2462</u>)

## ABSTRACT

25	ADSTRACT
26	Background: Sexual and gender expansive (SGE) individuals in Kazakhstan are disproportionately
27	affected by HIV yet stigma and discrimination pose ethical and practical challenges for HIV prevention
28	research involving them. Although researchers are tasked with ensuring that risks of research participation
29	are reasonable in relation to its benefits, participation-related risks and benefits-including negative and
30	positive social impacts (NSIs and PSIs respectively) on personal relationships, social status, health, and
31	other aspects of life—among SGE populations have received little attention.
32	Methods: We examined NSIs and PSIs of participation among SGE individuals in a three-city HIV
33	prevention study in Kazakhstan at the clinical trial's follow-up visits. We analyzed responses from 579
34	unique SGE participants who completed a total of 2648 follow-up visits over the 36-month study period
35	(2019–2022).
36	Results: Overall, NSIs were rare: 9 (2%) participants reported NSIs during the study; virtually no NSIs
37	( $\bar{x}$ =0.0037, SD=0.03) were reported at each follow-up visit. These few NSIs included 'trouble with
38	friends, family, or acquaintances' and 'other'. By contrast, PSIs were extensive: 515 (89%) participants
39	reported PSIs during the study; almost an average of five PSIs ( $\bar{x}$ =4.8, SD=3.4) were reported at each
40	follow-up visit. The most endorsed PSIs were 'gained knowledge', 'improvement in HIV-related issues',
41	and 'improvement in life'.
42	Conclusions: Our findings demonstrate the potential for HIV prevention research to be associated with
43	PSIs for SGE individuals experiencing stigmatization and discrimination. Future research should address
44	NSIs, particularly interpersonal challenges among network members, within HIV prevention research to
45	minimize risks and burdens of participation.
46	
47	ClinicalTrials.gov: NCT02786615

**Keywords:** HIV, clinical trials, ethics, men who have sex with men, transgender, Kazakhstan

#### INTRODUCTION

Globally, the number of new HIV infections has steadily declined over the past decade.<sup>1</sup> However, this progress has not been achieved equally across countries and key populations, with the number of new infections increasing in some contexts.<sup>1,2</sup> In Kazakhstan, where HIV incidence grew by 88% between 2010 and 2021,<sup>3</sup> sexual and gender expansive (SGE) individuals at elevated risk of HIV infection, particularly gay, bisexual, and other men who have sex with men (MSM) and transgender and nonbinary persons who have sex with men (TSM), are disproportionately affected by HIV across the HIV care continuum.<sup>4-6</sup>

A long line of research suggests that the enduring gaps in the HIV care continuum engagement 58 among SGE individuals may be attributed to stigma.<sup>7-9</sup> In Kazakhstan, multiple forms of stigma against 59 SGE individuals, such as sexual and gender-based victimization in community settings, bias-based 60 harassment in health care settings, and the absence of legal protection from discriminatory practices, have 61 been reported.<sup>10-13</sup> Moreover, among a sample of MSM and TSM in Kazakhstan, HIV stigma, internalized 62 homophobia, and sexual and gender-based victimization and discrimination were associated with 63 disruptions to HIV testing and treatment.<sup>14,15</sup> Furthermore, SGE individuals contend with multiple 64 behavioral risks associated with HIV that urge attention.<sup>16-18</sup> 65

Persistent stigma and discrimination pose ethical and practical challenges for research needed to 66 help develop locally effective means of decreasing HIV incidence. For instance, HIV research 67 participation may elicit and, in turn, be deterred by presumption of infection status, unwanted attention or 68 isolation, and other negative attitudes toward participants.<sup>19,20</sup> Further, confidentiality breach, despite 69 efforts to mitigate it, may occur during research and could reinforce social vulnerability among 70 participants.<sup>21</sup> Although researchers are tasked with ensuring that human subjects' risks of research 71 participation are reasonable in relation to benefits, the risk-benefit relationship may not always be 72 evident.<sup>22</sup> These risks and benefits include negative (NSIs) and positive social impacts (PSIs) pertaining 73 to personal relationships, social status, health, and other aspects of participants' lives.<sup>23</sup> Evidence in other 74 settings suggests that PSIs related to participation in HIV prevention research are prevalent, whereas NSIs 75

76	are uncommon. <sup>24-27</sup> Still, scientific literature on the assessment of NSIs and PSIs of HIV prevention
77	research participation among SGE individuals, particularly those in high stigma contexts, is sparse. We
78	sought to expand on this work by examining the overall incidence and correlates of NSIs and PSIs related
79	to HIV prevention research participation among a sample of MSM and TSM in Kazakhstan.
80	
81	METHODS
82	We used data from a stepped wedge clinical trial of an HIV preventive intervention for MSM and
83	TSM in Kazakhstan (NCT02786615). Briefly, the intervention involved crowdsourcing and peer-actuated
84	network approaches to increasing engagement of MSM and TSM in the HIV care continuum in
85	Kazakhstan. <sup>28</sup> After a period of collecting baseline data at participants' initial visits (July 2018 – February
86	2019), the intervention was implemented sequentially, across three Kazakhstan cities: Almaty, Shymkent,
87	and Astana. During the implementation phase, participants were invited to complete a manualized
88	intervention that was delivered over four sessions preceded by an orientation session. <sup>29</sup>
89	Throughout the trial, we conducted robust community engagement including community advisory
90	board sessions and recruitment venue site visits to help ensure safety and comfort in research
91	participation. This effort engaged community stakeholders in sharing their knowledge and wisdom of best
92	practices in conducting research involving SGE individuals in Kazakhstan. For instance, we inquired each
93	participant about preferred/appropriate term(s) to describe members of SGE communities and learned that
94	the term oft-used in research, 'sexual and gender minority', likely carries negative connotations in local
95	dialect. Finally, we implemented safety plans and staff training for risk mitigation, health care and social
96	service referrals, and regularly monitored social impacts during the trial.
97	

## 98 Participants

Eligibility criteria for the study included: being ≥18 years old; identifying as man or being
assigned male at birth; reporting consensual sex with a man in the past 12 months; reporting binge
drinking, drug use, or both in the past 90 days; and residing in a study city. For the purposes of the study,

we refer to participants as 'MSM', 'TSM', or 'SGE individuals', acknowledging the terms' limitation in
 thoroughly representing sexual and gender diversity among them.

104

#### 105 **Procedures**

Participants provided informed consent at their initial study visit. A structured behavioral survey 106 was administered by trained Research Assistants at the initial visit and follow-up visits every 6 months 107 until the end of the trial. All survey items were developed in English, translated to Russian and Kazakh, 108 and back-translated to English to ensure accuracy. Due to the stepped wedge study design, while most 109 participants completed six follow-up visits, those who were enrolled earlier in the trial had more follow-110 111 up visits scheduled compared to those enrolled later/closer to the end of the trial. Rapid HIV testing, counseling, and confirmatory testing or treatment referral for HIV, syphilis, gonorrhea, and chlamydia 112 were offered at the initial visit; the same services for HIV were offered at the final follow-up visit. Study 113 procedures were reviewed and approved by the Institutional Review Boards at Columbia University and 114 Al-Farabi Kazakh National University. 115

Between July 2018 and February 2022, 982 individuals were screened; of them, 649 (66%) were determined eligible for participation in the study. Of the study-eligible individuals, 629 (97%) returned for the initial visit; of them, 579 (92%) were subsequently retained for at least one follow-up visit. Social impacts related to HIV prevention research participation were assessed at follow-up visits. For this study, we used panel data from 579 participants who completed a total of 2,648 follow-up visits over a 36-month period (February 2019 – February 2022).

122

### 123 Measures

#### **124** Social Impact

Negative social impact (NSI) and positive social impact (PSI) items were adapted from the social
 impact assessment questionnaire used in a multinational HIV prevention study involving people who
 inject drugs.<sup>30</sup> For NSIs, participants were asked at each follow-up visit whether anything negative or

risky happened to them due to their study participation. Those reporting any negative incident were

probed about occurrences of specific NSIs (1=yes, 0=no). Similarly, for PSIs, participants were asked

130 whether anything positive or beneficial happened due to their study participation. Those reporting any

positive incident were probed about occurrences of specific PSIs (1=yes, 0=no).

#### 132 Alcohol and Drug Use

Alcohol and drug use assessment relied on the same measures used in previous studies.<sup>14,16,17</sup> Briefly, participants self-reported lifetime use of alcohol, marijuana, heroin and other opioids, stimulants, cocaine, hallucinogens or psychedelics, inhalants, and club drugs. Participants reporting any prior use of alcohol were asked about incidents of binge drinking, operationalized as "consuming five or more alcohol beverages within a two-hour period".<sup>31</sup> When appropriate, local or street names were used to describe the drugs. For alcohol, binge drinking, and each of the drugs, participants reporting any prior use were probed about the frequency of use in the past 90 days.

**140** Sociodemographic Characteristics

Participants self-reported their city of residence, age (in years), legal marital status, education
 completion status, employment status, gender identity, sex assigned at birth, sexual orientation, and HIV
 status. Participants reporting 'other' were asked to specify their responses.

144

145 Study Variables and Data Analysis

Social impacts were analyzed in two ways (1) per visit, in which each follow-up visit constitutes 146 a case, and (2) *per participant*, in which each participant's series of follow-ups constitutes a case. In other 147 words, the outcome data were structured in long format and wide format respectively, with long format 148 allowing for easy calculation of metrics using visits as the unit of analysis, and wide format involves 149 using study participants as the unit of analysis. For each set of NSI and PSI items in the long format data, 150 responses were summed to compose count variables of NSI and PSI items endorsed at each follow-up 151 visit; these variables were dichotomized to create dummy variables denoting any or no social impact. 152 Next, we transformed long format data into wide format. For each set of NSI and PSI items in the wide 153

format data, we calculated the averages of count variables across completed follow-up visits; these average count variables were dichotomized to create dummy variables so that the value of zero denoted no social impact, while values greater than zero denoted any social impact. Finally, for each social impact item, responses across completed follow-up visits were summed and dichotomized to create a dummy variable denoting any or no social impact during study participation.

Analysis of alcohol and drug use focused on use that was inconsistent with medical or legal guidance, and thus excluded alcohol use and included binge drinking and drug use. Responses for binge drinking were imputed as zero if no prior alcohol use was reported. Frequencies of binge drinking and drug use in the past 90 days were dichotomized to create dummy variables denoting any or no recent use. Frequencies were imputed as zero if no prior use was reported. The dichotomized responses for drug use across all drugs were summed and dichotomized to create a dummy variable denoting any or no drug use.

Responses for age were dichotomized as 'ages 18-24' and 'ages  $\geq 25$ ' categories based on clinical and cultural relevance.<sup>32,33</sup> If feasible and appropriate, write-in responses for the 'other' query for the sociodemographic characteristic items were inductively coded as existing response options, as determined by the authors (VV, YL, EW). In this way, all descriptions for the 'other' sexual orientation category were coded as 'bisexual.' At the initial visit, no participant reported being assigned 'other' sex at birth.

We conducted frequency analyses to describe the distributions of sociodemographic
characteristics and alcohol and drug use at the initial visit, as well as NSI and PSIs at follow-up visits.
Additionally, we performed linear regression analyses to test bivariate associations between
sociodemographic and alcohol and drug use factors at the initial visit and the average count of PSIs
endorsed across follow-up visits. We did not perform bivariate analyses for NSIs due to very small
numbers of NSIs reported (as presented in Results). All statistical analyses were performed using SPSS
version 28.0 (IBM Corp., Armonk, NY).

\_medRxiv\_SocialImpactsOfHIVResearchParticipation

Variable	n (%)
City of Residence	
Almaty	227 (39.2%)
Shymkent	184 (31.8%)
Astana	168 (29.0%)
Age groups, years (median=27; range=18-59)	
18-24	207 (35.8%)
25 or older	372 (64.2%)
Legal Marital Status	
Single, never married	455 (78.6%)
Else (e.g., married, no longer with spouse, other)	124 (21.4%
Education Completion Status	
High school	116 (20.0%
Vocational or college/university	463 (80.0%
Employment Status	
Employed (full-time or part-time)	447 (77.2%
Unemployed	63 (10.9%)
Else (e.g., retired, disability, homemaker, student, other)	69 (11.9%)
Gender Identity	
Woman	32 (5.5%)
Man	521 (90.0%
Other	26 (4.5%)
Sex Assigned at Birth	
Female	2 (0.3%)
Male	577 (99.7%
Sexual Orientation	
Straight	10 (1.7%)
Gay	305 (52.7%
Bisexual	264 (45.6%
Self-Reported HIV Status	
Positive	46 (7.9%)
Negative	387 (66.8%
Unknown	146 (25.2%
Drug Use, Lifetime	432 (74.6%
Drug Use, Past 90 Days	252 (43.5%
Binge Drinking, Lifetime	527 (91.0%
Binge Drinking, Past 90 Days	489 (84.5%

Table 1. Sociodemographic and Substance Use Characteristics a Sample of MSM and TSM in
 Kazakhstan at Initial Visit of an HIV Prevention Clinical Trial (*N*=579)

## RESULTS

181	Descriptive statistics for the initial-visit sociodemographic characteristics and alcohol and drug
182	use of the study sample of MSM and TSM who provided follow-up data are presented in Table 1.
183	Participants were between the ages of 18 and 59 (median=27). Most participants were single (79%),
184	employed (77%), and had completed vocational or college/university-level education (80%). With respect
185	to sexual and gender identities, most identified as man (90%) and sexually expansive, i.e., gay (53%) or
186	bisexual (46%). In this sample, 489 (85%) and 252 (44%) reported recent binge drinking and drug use,
187	respectively. A quarter of the sample reported unknown HIV status.
188	A graphical summary of participant responses for NSIs and PSIs is presented in Figure 1. In this
189	raster format, each row (i.e., raster line) represents a participant and the raster line is divided into
190	columns, with each column indicating whether NSIs and PSIs (Figures 1a and 1b, respectively) were
191	reported for the corresponding follow-up visit. The greater the number of NSIs (out of 6 items) or PSIs
192	(out of 14 items) reported during each visit, the more saturated the color (red for NSIs in Figure 1a and
193	green for PSIs in Figure 1b). If a participant did not complete a particular visit due to missing a scheduled
194	appointment, the follow-up visit falling after the end of the trial, or any other reason, that is indicated with
195	a yellow element in the raster line. Overall, the plots depict a higher volume of more-saturated green
196	raster lines than saturated red lines, indicating many more PSIs than NSIs were reported by participants at
197	each follow-up visit.

Figure 1. Raster<sup>a</sup> Plots of Negative Social Impacts and Positive Social Impacts of HIV Research
 Participation in a Sample of MSM and TSM in Kazakhstan (*N*=2648)



<sup>a</sup> Each raster line represents the reports from a single respondent

N/A = Data not available due to incomplete assessment and/or not applicable (due to enrollment at later points in the trial)

**Social Impacts Per Visit** 

- 202 Metrics regarding the distributions of NSIs and PSIs using the long format are presented in Table
- 203 2. Of 2648 follow-up visits, nine (0.3%) had a report of at least one NSI. Specifically, there were five
- 204 (0.2%) reports of 'trouble with friends, family, or acquaintances' and six (0.2%) reports of 'other NSI'
- involving 'loss of privacy' (n=4), 'stigma/harassment due to study participation' (n=1), and 'trouble with
- HIV-related issues' (*n*=1). By contrast, 1519 visits (57%) had respondents reporting at least one PSI.
- 207

**Table 2.** Negative Social Impacts and Positive Social Impacts of HIV Research Participation in a Sample of MSM and TSM in Kazakhstan (*N*=2648 visits)

Variable	n (%)
Any NSI	9 (0.3%)
Items	
Other NSI	6 (0.2%)
Trouble with friends, family, or acquaintances	5 (0.2%)
Arrested or trouble with police or other legal problems	0
Trouble getting or keeping housing	0
Trouble getting or keeping job, income, or economic support	0
Trouble getting health care or health insurance	0

Variable	n (%)
Any PSI	1519 (57.4%)
Items	
Gained knowledge	1445 (54.6%)
Improvement in HIV-related issues	1428 (53.9%)
Improvement in mental health	1162 (43.9%)
Improvement in life	1151 (43.5%)
Improvement in physical health	1133 (42.8%)
Improvement in (connection to) community	1107 (41.8%)
Improvement in relationships	1060 (40.0%)
Less homophobia or improvement in handling homophobia better	940 (35.5%)
Reduction of stigma	894 (33.8%)
Improvement in financial	770 (29.1%)
Improvement in employment	667 (25.2%)
Reduction in drug use	491 (18.5%)
Other PSI	457 (17.3%)
Less transphobia or improvement in handling transphobia better	408 (15.4%)

Table 3. Negative Social Impacts and Positive Social Impacts of HIV Research Participation in a
 Sample of MSM and TSM in Kazakhstan (*N*=579 participants)

<b>3a.</b> Negative Social Impacts (NSIs)	
Variable	n (%)
Any NSI	9 (1.6%)
Items	
Other NSI	6 (1.0%)
Trouble with friends, family, or acquaintances	5 (0.9%)
Arrested or trouble with police or other legal problems	0
Trouble getting or keeping housing	0
Trouble getting or keeping job, income, or economic support	0
Trouble getting health care or health insurance	0

Variable	n (%)
Any PSI	515 (88.9%)
Items	
Gained knowledge	501 (86.5%)
Improvement in HIV-related issues	499 (86.2%)
Improvement in mental health	461 (79.6%)
Improvement in life	447 (77.2%)
Improvement in (connection to) community	446 (77.0%)
Improvement in physical health	435 (75.1%)
Improvement in relationships	433 (74.8%)
Less homophobia or improvement in handling homophobia better	401 (69.3%)
Reduction of stigma	387 (66.8%
Improvement in financial	351 (60.6%)
Improvement in employment	324 (56.0%
Reduction in drug use	275 (47.5%)
Other PSI	266 (45.9%)
Less transphobia or improvement in handling transphobia better	237 (40.9%

## 213

## 214 Social Impacts Per Participant

215 Metrics regarding the distributions of NSIs and PSIs using the wide format are presented in Table

216 3. Of 579 MSM and TSM, nine individuals (2%) reported an NSI at least once across follow-up visits;

five (1%) reported 'trouble with friends, family, or acquaintances' and six (1%) reported 'other NSI'.

There was no report of NSIs related to legal, housing, economic, or health care issues. By contrast, 515

- 219 individuals (89%) reported a PSI at least once across follow-up visits. The majority of participants
- reported 'gained knowledge' (87%), 'improvement in HIV-related issues' (86%), and 'improvement in
- life' (80%); fewer participants reported 'less transphobia or improvement in handling it better' (41%),

222	'reduction in drug use' (48%), and 'other PSI' (46%), but these numbers still approached approximately				
223	half of participants. Participants reported, on average, five PSIs ( $\bar{x}$ =4.8, SD=3.4) and zero NSI ( $\bar{x}$ =0.0037,				
224	<i>SD</i> =0.03) during the trial.				
225					
226	<b>Correlates of Positive Social Impacts</b>				
227	Partial results of the bivariate analyses illustrating st	tatistically sig	nificant c	orrelates of th	e
228	average count of PSIs—residence and recent binge drinking	are present	ed in Tab	le 4. On avera	ge, living
229	in Shymkent and Astana, compared with Almaty, was assoc	iated with 2.8	s-point and	1 1.3-point hig	gher
230	average count of PSIs, respectively. Recent binge drinking w	was associated	d with, on	average, a 1.2	2-point
231	higher average count of PSIs.				
232					
233 234	Table 4. Significant Bivariate Associations Between the           Impacts Endorsed Across Follow-Up Visits and Sociod           Characteristics at Initial Visit in a Sample of MSM and	lemographic	and Sub	stance Use	al
235	Variable City of Residence Almaty Shymkent	β Ref. 2.8	0.3	95% CI	<u>p</u> <.001
235	Variable City of Residence Almaty Shymkent Astana	β Ref. 2.8 1.3	SE 0.3 0.3	<b>95% CI</b> (2.2, 3.5) (0.7, 1.9)	<.001 <.001
235	Variable City of Residence Almaty Shymkent	β Ref. 2.8	<b>SE</b>	<b>95% CI</b> (2.2, 3.5)	<.001
	Variable         City of Residence         Almaty         Shymkent         Astana         Binge Drinking, Past 90 Days         SE: Standard Error	β Ref. 2.8 1.3 1.2	SE 0.3 0.3	<b>95% CI</b> (2.2, 3.5) (0.7, 1.9)	<.001 <.001
236	Variable         City of Residence         Almaty         Shymkent         Astana         Binge Drinking, Past 90 Days         SE: Standard Error         CI: Confidence Interval	β Ref. 2.8 1.3 1.2	<b>SE</b> 0.3 0.3 0.4	<b>95% CI</b> (2.2, 3.5) (0.7, 1.9) (0.4, 2.0)	<.001 <.001 .002
236 237	Variable         City of Residence         Almaty         Shymkent         Astana         Binge Drinking, Past 90 Days         SE: Standard Error         CI: Confidence Interval         DISCUSSION	β Ref. 2.8 1.3 1.2 N ion clinical tr	<i>SE</i> 0.3 0.3 0.4	<b>95% CI</b> (2.2, 3.5) (0.7, 1.9) (0.4, 2.0)	<.001 <.001 .002
236 237 238	Variable         City of Residence         Almaty         Shymkent         Astana         Binge Drinking, Past 90 Days         SE: Standard Error         CI: Confidence Interval         DISCUSSION         Among MSM and TSM enrolled in an HIV prevention	β Ref. 2.8 1.3 1.2 N ion clinical tr es than NSIs.	SE 0.3 0.3 0.4 ial in Kaza Specifica	95% CI (2.2, 3.5) (0.7, 1.9) (0.4, 2.0)	<.001 <.001 .002
236 237 238 239	Variable         City of Residence         Almaty         Shymkent         Astana         Binge Drinking, Past 90 Days         SE: Standard Error         CI: Confidence Interval         DISCUSSION         Among MSM and TSM enrolled in an HIV prevention         study participation were endorsed at substantially higher rate	β Ref. 2.8 1.3 1.2 N ion clinical tr es than NSIs. per follow-uj	SE 0.3 0.3 0.4 ial in Kaza Specifica	95% CI (2.2, 3.5) (0.7, 1.9) (0.4, 2.0) akhstan, PSIs lly, NSIs were per participar	<.001 <.001 .002
236 237 238 239 240	Variable         City of Residence         Almaty         Shymkent         Astana         Binge Drinking, Past 90 Days         SE: Standard Error         CI: Confidence Interval         DISCUSSION         Among MSM and TSM enrolled in an HIV prevention         study participation were endorsed at substantially higher rate         infrequently reported, with an average of virtually zero NSI	β Ref. 2.8 1.3 1.2 N ion clinical tr es than NSIs. per follow-up five PSIs per	SE 0.3 0.3 0.4 ial in Kaza Specifica o visit and visit. To o	95% CI (2.2, 3.5) (0.7, 1.9) (0.4, 2.0) akhstan, PSIs lly, NSIs were per participar pur knowledge	<.001 <.001 .002
236 237 238 239 240 241	Variable         City of Residence         Almaty         Shymkent         Astana         Binge Drinking, Past 90 Days         SE: Standard Error         CI: Confidence Interval         DISCUSSION         Among MSM and TSM enrolled in an HIV prevention         study participation were endorsed at substantially higher rate         infrequently reported, with an average of virtually zero NSI         whereas PSIs were reported extensively, with an average of	β Ref. 2.8 1.3 1.2 N ion clinical tr es than NSIs. per follow-up five PSIs per	SE 0.3 0.3 0.4 ial in Kaza Specifica o visit and visit. To o	95% CI (2.2, 3.5) (0.7, 1.9) (0.4, 2.0) akhstan, PSIs lly, NSIs were per participar pur knowledge	<.001 <.001 .002

In our study, the most frequently endorsed PSIs were 'gained knowledge', 'improvement in HIVrelated issues', and 'improvement in mental health'. The parent study was testing the efficacy of a social network-based intervention for increasing engagement of MSM and TSM in the HIV care continuum in Kazakhstan. A primary objective of the intervention was supporting MSM and TSM with promoting the uptake of HIV care services within their networks. Therefore, receipt of or indirect exposure to the intervention could have contributed to improvement of knowledge and HIV-related issues among participants.

Our findings are consistent with other studies demonstrating common experiences of PSIs and 251 scant reports of NSIs. A multinational HIV prevention trial involving people who inject drugs in China 252 and Thailand similarly found that 77% of participants reported PSIs, far exceeding 0.5% reporting NSIs.<sup>24</sup> 253 A cross-protocol analysis of data from 413 preventive HIV vaccine trials in 13 countries showed that 81% 254 of participants reported PSIs and 8% reported NSIs.<sup>25</sup> Finally, an HIV cure-related trial involving women 255 living with HIV in the U.S. demonstrated reporting of a greater number of PSIs than NSIs by participants 256 at their exit survey.<sup>26</sup> Our study extends this line of inquiry by contributing analyses of responses from 257 SGE individuals in Kazakhstan. 258

In our study, participants reporting recent binge drinking were more likely to report a greater 259 number of PSIs. Binge drinking is associated with increased risk of developing health and psychosocial 260 problems. Since the trial intervention also focused on increasing engagement in alcohol and drug use 261 treatment, it is possible that participants reporting binge drinking perceived the intervention to be 262 beneficial and valuable more so than those reporting no binge drinking. Moreover, participants living in 263 Shymkent and Astana were more likely to report a greater number of PSIs. In previous studies, 264 geographical differences in PSI endorsement had been attributed to variability in access to resources.<sup>25,30</sup> 265 Given that twice as many MSM and TSM were estimated to be living in Almaty as Shymkent or Astana, 266 it is reasonable to posit that participants in Almaty may have been benefiting from having greater 267 268 availability of and access to resources outside the study.<sup>5</sup>

Although relatively rare, NSIs warrant careful review and, as necessary, development of 269 mitigation strategies. In our study, the most frequently endorsed NSIs were 'other NSI' and 'trouble with 270 friends, family, or acquaintances'. Other NSIs mostly entailed loss of privacy due to breach of 271 confidentiality by an entity (e.g., HIV care provider) or an individual—in at least one case, by another 272 273 study participant. One participant in our study recounted online criticisms about their study participation. Breach of confidentiality had been reported as an NSI in a multinational preventive HIV vaccine trial.<sup>25</sup> In 274 addition, navigating unwanted attention or aggression regarding study participation through confrontation 275 or avoidance had been reported in other studies,<sup>22,26</sup> and could be interpreted as trouble with personal 276 relationships. Indeed, in our study, trouble with friends, family, or acquaintances was endorsed by five out 277 of nine participants reporting any NSI. Although we confirmed with participants that NSIs had not 278 resulted due to administration of study procedures, they nonetheless stress the importance of developing 279 and implementing safety plans to mitigate potential NSIs. 280

Limitations to our study can inform future research. In this study, assessment of NSIs and PSIs 281 pertained to experiences of research study participation and did not specify a timeframe. Responses at 282 subsequent follow-up visits could reflect prior experiences and, therefore, lead us to capture individual 283 PSIs and NSIs multiple times. This limitation does not impact participant-level results; however, future 284 studies interested in time-sequencing of NSIs and PSIs can overcome this limitation by specifying a 285 timeframe, e.g., since the most recent prior study visit. Also, given that our social impact questionnaires 286 reflected categories of impacts that could be interpreted in different ways, future research should 287 cognitively test the questionnaire items (following translation) to ensure accuracy in the local context. 288 Next, endorsement of social impacts may be subject to social response bias. In other settings, it has been 289 speculated that fear of losing tangible benefits, such as medical care and compensation, could lead to 290 underreporting of NSIs.<sup>25</sup> It is possible that study participants underreported NSIs to avoid losing 291 HIV/STI testing and counseling/referral, compensation provided for their participation, or both. Training 292 of staff on data collection procedures ensuring response accuracy should be prioritized. Finally, our 293 findings may not be generalizable to all MSM and TSM in Kazakhstan. This analysis was restricted to 294

data provided by SGE individuals retained in an HIV prevention trial conducted in three Kazakhstan 295 cities over a three-year period and, thus, did not represent experiences of those who did not participate in 296 or had been excluded from the trial (e.g., those without recent drug use or binge drinking). However, we 297 recruited a large sample of MSM and TSM from multiple cities in Kazakhstan (the first study to do so to 298 our knowledge) and retention rates were high, enabling us to obtain diverse perspectives on NSI and PSI 299 300 from this population. Moreover, given that drug use and binge drinking are also stigmatized, participants in our study likely experience more stigma compared to their peers who do not engage in these behaviors 301 —lending confidence to our conclusion that HIV prevention research overwhelmingly leads to PSIs in a 302 high-stigma context. At the same time, despite extensive retention efforts, missing data were incurred 303 304 through participant dropout and loss to follow-up. It is possible that attrition was related to anticipation of NSI or absence of PSI. As such, future studies specifically designed to assess PSIs and NSIs among MSM 305 and TSM in high-stigma contexts is warranted to bolster assessment of ethics of conducting HIV 306 prevention research among stigmatized groups. 307

308

309

#### CONCLUSIONS

Our study adds to the literature on social impact assessment in HIV prevention trials and 310 highlights the ethical significance of assessing participant-centered experiences. PSIs and NSIs identified 311 312 in this study suggest that it is possible to ethically conduct HIV prevention research involving SGE individuals at elevated risk of HIV infection in Kazakhstan despite the context of intersecting stigma. As 313 314 risk mitigation is an important ethical consideration in HIV prevention, the infrequent reporting of NSIs in our study is encouraging. It is possible that procedures embedded in our trial to anticipate and address 315 ethical issues contributed to such an outcome. These procedures included, but were not limited to, 316 involving SGE individuals, as paid staff, or community advisory board members, in all aspects of the 317 trial, training staff on protecting the safety, privacy, and confidentiality of participants, creating an 318 319 affirming environment for research participation, hosting social events for building rapport and comfort, and reviewing and sharing study findings with SGE communities and service providers. 320

321	Several recommendations are derived from this study: (1) partner with SGE communities in all
322	aspects of research; (2) develop safety plans, including risk mitigation strategies, tailored to the needs of
323	SGE communities and features of research settings/platforms; <sup>34,35</sup> (3) embed systematic assessment of
324	social impacts related to study participation; (4) include PSIs in evaluating the ethics of conducting
325	research; <sup>36</sup> and (5) facilitate feedback and communication with SGE communities to ensure researcher
326	accountability. These recommendations may serve as a guide for conducting HIV prevention research in
327	settings where diverse sexual and gender characteristics are stigmatized with few NSIs and many PSIs.

328	STATEMENTS AND DECLARATIONS
329	Acknowledgements
330	We would like to thank the project staff of the Columbia University Global Health Research Center of
331	Central Asia—including Karina Alipova, Farruh Aripov, Olga Balabekova, Daniya Bekishev, Dilara
332	Belkesheva, Valeriya Davydova, Ferangiz Hasanova, Sultana Kali, Saltanat Kuskulova, Aitkul Nazarova,
333	Syrym Omirbek, Svyatoslov Suslov, Aizhan Toleuova, Aidar Yelkeyev, and Saida Yessenova-for their
334	commitment and care given to the execution of study activities. We would like to thank the participants
335	for their courage and time in sharing their stories.
336	
337	Declaration of competing interest
338	Jeremy Sugarman is a member of Merck KGaA Ethics Advisory Panel and Stem Cell Research Oversight
339	Committee; a member of IQVIA's Ethics Advisory Panel; a member of Aspen Neurosciences Clinical
340	Advisory Panel; and a consultant to Merck. None of these activities is related to the material discussed in
341	this manuscript.
342	
343	The other authors have no competing financial or non-financial interest to declare.
344	
345	Funding sources
346	This study was supported by the National Institute on Drug Abuse [grant R01DA040513 (PI: Wu)].
347	Emily Allen Paine's time was supported by the National Institute of Mental Health [grants
348	K01MH128117 (PI: Paine) and P30MH43520 (PI: Remien)].
349	
350	Data availability
254	Deidentified data used in this study could be made available from the corresponding author upon

- 351 Deidentified data used in this study could be made available from the corresponding author upon
- 352 reasonable request.

353		REFERENCES
354	1.	Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2023. 2023. Available at:
355		https://www.unaids.org/en/resources/documents/2023/2023_unaids_data.
356	2.	Joint United Nations Programme on HIV/AIDS (UNAIDS). Miles to go - The response to HIV in
357		eastern Europe and central Asia. 2018. Available at:
358		https://www.unaids.org/en/resources/documents/2018/miles-to-go_eastern-europe-and-central-asia.
359	3.	Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2022. 2022. Available at:
360		https://www.unaids.org/en/resources/documents/2023/2022_unaids_data.
361	4.	Eurasian Coalition on Male Health (ECOM). Brief on HIV among MSM in Kazakhstan. 2018.
362		Available at: https://ecom.ngo/library/brief-kazakhstan-en.
363	5.	Wu E, Terlikbayeva A, Hunt T, Primbetova S, Lee YG, Berry M. Preliminary population size
364		estimation of men who have sex with men in Kazakhstan: Implications for HIV testing and
365		surveillance. LGBT Health. 2016;4:164-167. doi:10.1089/lgbt.2015.0152
366	6.	Wu E, Lee YG, Zhakupova G, et al. Prevalence and correlates of HIV infection and unknown HIV
367		infection among men who have sex with men (MSM) in Kazakhstan: Evidence for a brewing
368		syndemic from a multi-city study. Presented at: 23rd International AIDS Conference (AIDS 2020);
369		2020; Virtual.
370	7.	Arreola S, Santos G-M, Beck J, et al. Sexual stigma, criminalization, investment, and access to HIV
371		services among men who have sex with men worldwide. AIDS Behav. 2015;19:227-234.
372		doi:10.1007/s10461-014-0869-x
373	8.	Babel RA, Wang P, Alessi EJ, Raymond HF, Wei C. Stigma, HIV risk, and access to HIV prevention
374		and treatment services among men who have sex with men (MSM) in the United States: A scoping
375		review. AIDS Behav. 2021;25:3574-3604. doi:10.1007/s10461-021-03262-4
376	9.	Vaitses Fontanari AM, Zanella GI, Feijó M, Churchill S, Rodrigues Lobato MI, Costa AB. HIV-
377		related care for transgender people: A systematic review of studies from around the world. Soc Sci
378		Med. 2019;230:280-294. doi:10.1016/j.socscimed.2019.03.016

- 10. ALMA-TQ, Law CfIHRoNPSo, Rights GIfH. *Violations by Kazakhstan of the Right of Transgender*
- 380 *Persons to Legal Recognition of Gender Identity*. 2016. Available at:
- 381 https://www.kok.team/files/files/article/386/int-ccpr-css-kaz-24305-e.pdf
- 11. Eurasian Coalition on Male Health (ECOM). *Legislative Analaysis Related to SOGI and HIV in*
- 383 *Kazakhstan*. 2021. Available at: https://ecom.ngo/library/kazakhstan-legislative-analysis\_2020\_en
- 12. Levitanus M. Agency and resistance amongst queer people in Kazakhstan. *Centr Asian Surv*.
- 385 2022;41:498-515. doi:10.1080/02634937.2021.2008874
- 13. Laughney CI, Lee YG, Mergenova G, et al. Earlier sexual debut and anti-gay victimization among
- men who have sex with men (MSM) in Kazakhstan. J Interpers Violence. 2023;38:10795-10813.
- 388 doi:10.1177/08862605231176800
- 14. Paine EA, Lee YG, Vinogradov V, et al. HIV Stigma, homophobia, sexual and gender minority
- community connectedness and HIV testing among gay, bisexual, and other men and transgender
- <sup>391</sup> people who have sex with men in Kazakhstan. *AIDS Behav.* 2021;25:2568-2577.
- doi:10.1007/s10461-021-03217-9
- 15. Paine EA, Lee YG, Mergenova G, et al. Compounding vulnerabilities: Victimization and
- discrimination is associated with COVID-19 disruptions to HIV-related care among gay, bisexual,
- and other men and transgender and nonbinary people who have sex with men in Kazakhstan. AIDS
- 396 *Care*. 2023;35:651-657. doi:10.1080/09540121.2022.2148956
- 16. Lee YG, Zhakupova G, Vinogradov V, et al. Polydrug use, sexual risk, and HIV testing among
- cisgender gay, bisexual, and other men and transgender and nonbinary individuals who have sex with
- 399 men in Kazakhstan. *AIDS Educ Prev*. 2022;34:413-426. doi:10.1521/aeap.2022.34.5.413
- 400 17. Laughney CI, Lee YG, Mergenova G, et al. Earlier sexual debut as a risk factor for substance use
- 401 among men who have sex with men (MSM) in Kazakhstan. *Glob Soc Welf*.
- 402 2023;doi:10.1007/s40609-023-00298-3

- 18. Laughney CI, Lee YG, Mergenova G, et al. Earlier sexual debut and exchange sex among men who
- 404 have sex with men (MSM) in Kazakhstan. J Sex Res. 2023;60:919-924.
- 405 doi:10.1080/00224499.2023.2167064
- MacQueen K, Shapiro K, Karim Q, Sugarman J. Ethical challenges in international HIV prevention
   research. *Account Res.* 2004;11:49-61. doi:10.1080/08989620490280230
- 20. Bass SB, D'Avanzo P, Alhajji M, et al. Exploring the engagement of racial and ethnic minorities in
- 409 HIV treatment and vaccine clinical trials: A scoping review of literature and implications for future
- 410 research. *AIDS Patient Care STDs*. 2020;34:399-416. doi:10.1089/apc.2020.0008
- 411 21. Azhar S, Tao X, Jokhakar V, Fisher CB. Barriers and facilitators to participation in Long-acting
- injectable PrEP research trials for MSM, transgender women, and gender-nonconforming people of
- 413 color. *AIDS Educ Prev.* 2021;33:465-482. doi:10.1521/aeap.2021.33.6.465
- 22. Gilbertson A, Kelly EP, Rennie S, Henderson G, Kuruc J, Tucker JD. Indirect benefits in HIV cure
  clinical research: A qualitative analysis. *AIDS Res Hum Retroviruses*. 2018;35:100-107.
- 416 doi:10.1089/aid.2017.0224
- 23. Allen M, Lau C-Y. Social impact of preventive HIV vaccine clinical trial participation: A model of
- prevention, assessment and intervention. *Soc Sci Med.* 2008;66:945-951.
- doi:10.1016/j.socscimed.2007.10.019
- 420 24. Sugarman J, Stalter R, Bokoch K, Liu T-Y, Donnell D. Positive social impacts related to participation
  421 in an HIV prevention trial involving people who inject drugs. *IRB*. 2015;37:17-19.
- 422 25. Andrasik MP, Sesay FA, Isaacs A, Oseso L, Allen M. Social impacts among participants in HIV
- 423 Vaccine Trial Network (HVTN) preventive HIV vaccine trials. *J Acquir Immune Defic Syndr*.
- 424 2020;84:488-496. doi: 10.1097/QAI.00000000002369
- 26. Dubé K, Hosey L, Starr K, et al. Participant perspectives in an HIV cure-related trial conducted
- 426 exclusively in women in the United States: Results from AIDS clinical trials group 5366. AIDS Res
- 427 Hum Retroviruses. 2020;36:268-282. doi:10.1089/aid.2019.0284

- 27. Dubé K, Shelton B, Patel H, et al. Perceived risks and benefits of enrolling people with HIV at the
  end of life in cure research in Southern California, United States. *J Virus Erad.* 2023;9:100328.
  doi:https://doi.org/10.1016/j.jve.2023.100328
- 28. Wu E. Using social media and social networks to increase access to HIV care among MSM in three
  cities in Kazakhstan: Project UNI. Presented at: 22nd International AIDS Conference (AIDS 2018);
- 433 2018; Amsterdam, Netherlands.
- Wu E, Lee YG, Vinogradov V, et al. Intervention adaptation and implementation method for realworld constraints and using new technologies. *Res Soc Work Pract*. 2022;33:562-570.
- doi:10.1177/10497315221120605
- 30. Sugarman J, Trumble I, Hamilton E, et al. Reported participation benefits in international HIV
  prevention research with people who inject drugs. *Ethics Hum Res.* 2019;41:28-34.
- doi:10.1002/eahr.500030
- 440 31. National Institute on Alcohol Abuse and Alcoholism. *Drinking Levels Defined*. Available at:
- 441 https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking
- 442 32. Berry M, Wirtz AL, Janayeva A, et al. Risk factors for HIV and unprotected anal intercourse among
- 443 men who have sex with men (MSM) in Almaty, Kazakhstan. *PLoS One*. 2012;7:e43071.
- doi:10.1371/journal.pone.0043071
- 445 33. World Health Organization (WHO). *Adolescent and Young Adult Health*. Available at:
- 446 https://www.who.int/news-room/fact-sheets/detail/adolescents-health-risks-and-solutions
- 447 34. Fisher CB, Bragard E, Bloom R. Ethical considerations in HIV eHealth intervention research:
- 448 Implications for informational risk in recruitment, data maintenance, and consent procedures. *Curr*
- 449 *HIV/AIDS Rep.* 2020;17:180-189. doi:10.1007/s11904-020-00489-z
- 450 35. Sugarman J, Barnes M, Rose S, et al. Development and implementation of participant safety plans for
- 451 international research with stigmatised populations. *Lancet HIV*. 2018;5:e468-e472.
- 452 doi:10.1016/S2352-3018(18)30073-0

- 453 36. Rennie S, Day S, Mathews A, et al. The role of inclusion benefits in ethics committee assessment of
- 454 research studies. *Ethics Hum Res.* 2019;41:13-22. doi:10.1002/eahr.500015